Abstract: The present invention provides a crystal form of urate transporter 1 inhibitor and a preparation method and use thereof. The crystal form is characterized by a stable state of appearance and a capability of further improving the purity and storage stability of the compound, etc., and suitable as a pharmaceutical raw material.

Abstract: The present disclosure provides a method for domesticating Saccharomyces cerevisiae which is resistant to fermentation inhibitors, high temperature and high concentration of ethanol. The method comprises a primary domestication and a secondary domestication of the S. cerevisiae, wherein the primary domestication comprises the steps of replacing the fermented mash with fresh liquefied mash and continuing fermentation when the ethanol content in the fermented mash reaches a higher concentration (>12% (v/v)), the replacement is performed for at least 20 times, and the time interval of replacements is 20-30 hours; the secondary domestication comprises the steps of performing high-temperature domestication on the primary domesticated strain by a temperature gradient and replacing the fermented mash for multiple times, wherein the temperature is raised by 0.5° C.-2° C. every 18-24 times of replacement. The domesticated S.

Abstract: The present disclosure provides a method for domesticating Saccharomyces cerevisiae which is resistant to fermentation inhibitors, high temperature and high concentration of ethanol. The method comprises a primary domestication and a secondary domestication of the S. cerevisiae, wherein the primary domestication comprises the steps of replacing the fermented mash with fresh liquefied mash and continuing fermentation when the ethanol content in the fermented mash reaches a higher concentration (>12% (v/v)), the replacement is performed for at least 20 times, and the time interval of replacements is 20-30 hours; the secondary domestication comprises the steps of performing high-temperature domestication on the primary domesticated strain by a temperature gradient and replacing the fermented mash for multiple times, wherein the temperature is raised by 0.5° C.-2° C. every 18-24 times of replacement. The domesticated S.

Abstract: The present invention relates to the pharmaceutical field for the treatment of hyperuricemia and gout. In particular, the present invention relates to a carboxylic acid urate transporter 1 (URAT1) inhibitor of a general formula (I) containing a diarylmethane structure and a preparation method thereof, and a pharmaceutical composition containing the same and a use thereof in the preparation of medicaments for treating hyperuricemia and gout, wherein R1 is selected from H, C1-C10 alkyl, C3-C10 cycloalkyl, F, Cl, Br, I, CN, NO2, SR4 or OR4; R2 is selected from H, F, Cl, Br or I; R3 is selected from H or C1-C4 alkyl; X is selected from S or CH2; wherein R4 is selected from C1-C10 alkyl.

Abstract: Provided is a method for preparing a URAT1 inhibitor, 2-((5-bromo-4-((4-bromonaphthalen-1-yl)methyl)-4H-1,2,4-triazol-3-yl)thio) acetic acid represented by the following formula ZXS-BR, the reaction equation of which being shown as follows. Compared with the prior art, the preparation method provided by the present application is of low cost, ease of handling, ease of quality control, and applicable to industrialization.

Abstract: The present invention provides a phenyl C-glucoside derivative containing a deoxyglucose structure as represented by formula I, preparation method thereof, a pharmaceutical composition comprising the same, and uses thereof in the preparation of medicaments for treating diabetes, wherein substituents R1-R7 are as defined in the specification. The present invention also provides a method for synthesizing the phenyl C-glucoside derivative containing a deoxyglucose structure and an intermediate product. The method has advantages of being simple to manage and of low cost, which is suitable for large-scale industrial production. The present invention further provides a cocrystal of (1S)-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-D-glucose and L-proline, and preparation method and uses thereof.